The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...
Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...
Accropeutics Inc. (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in...
A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...
The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infec...
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced long-term results from the OlympiA Phase 3 trial w...
In an exclusive interview with BioPharma Boardroom, Dr. Mehmood Khan, Chief Executive Officer of Hevolution Foundation, shares insights into the tr...
First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infections Two phase 1/2 cl...
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdege...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...
AbbVie (NYSE: ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monot...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...
© 2025 Biopharma Boardroom. All Rights Reserved.
